Revenue segments as reported by the company.

Products

Premiums

Services

Net investment income

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Benefit costs

Operating expenses

Goodwill impairment

Store impairments

Opioid litigation charges

Loss on assets held for sale

Restructuring charge

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

CVS Health

Aetna is an American managed health care company, which sells traditional and consumer directed health care insurance plans and related services, such as medical, pharmaceutical, dental, behavioral health, long-term care, and disability plans. Aetna is a member of the Fortune 500.

Aetna

CVS Pharmacy is a subsidiary of the American retail and health care company CVS Health, headquartered in Woonsocket, Rhode Island. It was also known as, and originally named the Consumer Value Store and was founded in Lowell, Massachusetts, in 1963. The chain was owned by its original holding company Melville Corporation since its inception until its current parent company CVS Health was spun off into its own company in 1996. CVS Pharmacy is currently the largest pharmacy chain in the United States by number of locations (over 9,600 as of 2016) and total prescription revenue. As the retail pharmacy division of CVS Health, it ranks as the 7th largest U.S. corporation according to Fortune 500 in 2016. CVS Pharmacy's leading competitor Walgreens Boots Alliance ranked 37th.

CVS Pharmacy

CVS Health Corp. is a health solutions company, which engages in the provision of healthcare services. It operates through the following segments: Health Care Benefits, Health Services, Pharmacy and Consumer Wellness, and Corporate and Other. The Health Care Benefits segment operates as a health care benefits provider. The Health Services segment offers a full range of PBM solutions, delivers health care services in its medical clinics, virtually, and in the home. The Pharmacy & Consumer Wellness segment dispenses prescriptions in its retail pharmacies and through its infusion operations. The Corporate and Other Segment is involved in management and administrative expenses. The company was founded by Stanley P. Goldstein and Ralph Hoagland in 1963 and is headquartered in Woonsocket, RI.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

CVS Health exceeds Q4 expectations, eyes growth with Oak Street

CVS Health's strong financial performance in 2022, driven by revenue growth and exceeding EPS expectations, positions the company well for future growth.
The acquisition of Oak Street Health presents opportunities to expand into primary care and improve long-term earnings growth, despite challenges in maintaining retail performance.

CVS Health excels in Q1, eyes growth through acquisitions and innovation

CVS Health's strong financial performance, strategic acquisitions, and customer-centric initiatives position the company for sustained growth and competitive advantage.
While facing challenges in the evolving healthcare landscape, CVS Health's focus on innovation, affordability, and operational efficiency provides a solid foundation for future success.
By capitalizing on opportunities in growth, synergies, and healthcare services, CVS Health can navigate industry headwinds and drive long-term value creation for stakeholders.

CVS Health reports robust Q2 earnings, eyes growth opportunities

CVS Health's Q2 2023 performance reflects strong financial results and strategic acquisitions driving growth.
Despite challenges like higher costs and restructuring charges, the company remains confident in its ability to deliver outstanding performance.
Opportunities lie in expanding Medicaid contracts, biosimilar market establishment, and clinic openings for at-risk populations.
Overall, CVS Health's focus on cost optimization, digital sales growth, and patient engagement positions it well for future success.

CVS Health reports robust Q3 earnings and strategic growth plans

CVS Health's Q3 performance reflects strong financial results and strategic initiatives across its segments, positioning the company for sustainable growth.
While facing challenges like declining vaccine demand and contract losses, CVS Health is focused on leveraging opportunities in biosimilars and cost-saving solutions.
The company's commitment to operational excellence, innovation, and workforce investment underscores its strategic vision for becoming a leading health solutions provider.
With a clear focus on growth drivers and mitigating challenges, CVS Health is poised to capitalize on market opportunities and deliver value to shareholders.

CVS Health reports robust Q4 earnings, eyes Medicare margin recovery

CVS Health's Q4 2023 earnings call highlighted strong financial performance, a cautious stance on Medicare Advantage utilization, and a focus on transforming healthcare delivery. The company is committed to margin recovery, growth, and enhancing customer experience while addressing challenges in Medicare Advantage trends and cost pressures.

CVS Health faces Medicare Advantage challenges, focuses on margin improvement

CVS Health's Q1 2024 earnings call highlighted strong financial performance, challenges in the Medicare Advantage business, and a focus on improving margins. The company showcased strengths in the biosimilar market and Pharmacy & Consumer Wellness segment while addressing issues impacting Health Care Benefits and Services segments.

CVS Health's Q2 2024 performance reflects strong financial results, cost savings, and innovative initiatives in pharmacy services.
The company faces challenges in the Health Care Benefits segment but is actively addressing them through leadership changes and operational improvements.
Opportunities for growth include driving margin improvements, expanding digital reach, and educating stakeholders on the value delivery of PBMs.
Expectation of margin recovery in Medicare Advantage and double-digit EPS growth in 2025 highlight CVS Health's strategic focus on operational efficiencies and cost savings.

CVS Health reports robust Q3 earnings, focuses on growth strategies

CVS Health's Q3 2024 performance was marked by strong financial results, leadership changes, and segment-specific challenges and successes. The company is focused on leveraging opportunities in strategic initiatives and addressing areas for improvement to drive future growth.

Revenue

Cost of revenue

Gross profit

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CVS Health said Shawn Guertin, its top finance executive who has been on a leave of absence since October due to family health reasons, won't return to the healthcare-services giant.

CVS Names Cowhey Permanent Finance Chief as Guertin Departs

CVS Health said on Friday enrollment for 2024 in some of its Medicare Advantage plans, through which it provides health insurance for people aged 65 and older, exceeded its expectations.

CVS says 2024 Medicare Advantage enrollment exceeds expectations

CVS Health Corp. CVS, -0.46% said Friday it has appointed Tom Cowhey, currently senior vice president of corporate finance and interim chief financial officer as its permanent CFO. The drug store chain named Mike Pykosz, CEO of Oak Street Health, as president of health care delivery.

CVS names interim CFO Tom Cowhey as permanent finance chief

Thomas F. Cowhey named Chief Financial Officer Mike Pykosz named President of Health Care Delivery  WOONSOCKET, R.I. , Jan. 5, 2024 /PRNewswire/ -- CVS Health® (NYSE: CVS) today announced several leadership updates, effective immediately: Senior Vice President of Corporate Finance and interim CFO, Tom Cowhey, has been formally appointed the company's next CFO.

CVS Health announces leadership appointments

CVS Health (CVS) closed the most recent trading day at $80.51, moving -0.46% from the previous trading session.

Here's Why CVS Health (CVS) Fell More Than Broader Market

CVS Pharmacy, the retail division of CVS Health, simplified its loyalty program by consolidating it into one membership with two tiers. With both tiers of the ExtraCare program, CVS Pharmacy will offer in-store savings, online sales and personalized deals that will be emailed or texted to members, the company said in a Thursday (Jan.

CVS Pharmacy Launches Simplified, Two-Tiered Loyalty Program

AbbVie

Abbvie Inc (NYSE:ABBV) shares recovered in the early afternoon Thursday after dipping 3% in after hours trade the evening prior on the news that CVS Health Corp (NYSE:CVS) announced it will remove Humira, a leading rheumatoid arthritis medication, from some preferred drug lists for reimbursement starting April 1, endorsing biosimilar alternatives. Sandoz's Hyrimoz and an unbranded version of Humira, along with Biocon's near-copy drugs, will be preferred on CVS formularies.

AbbVie shares higher following ‘overdone' reaction to CVS move to replace top-selling arthritis drug

ExtraCare ® is now one easy savings membership with two tiers WOONSOCKET, R.I. , Jan. 4, 2024 /PRNewswire/ -- CVS Pharmacy ® , the retail division of CVS Health® (NYSE: CVS), today announced the evolution of its loyalty program to include two membership tiers: ExtraCare ® and ExtraCare Plus™.

CVS Pharmacy® announces new simplified loyalty experience

Abbvie Inc (NYSE:ABBV) shares fell after hours on Wednesday after CVS Health Corp announced it will remove Humira, a leading rheumatoid arthritis medication, from some preferred drug lists for reimbursement starting April 1, endorsing biosimilar alternatives. Sandoz's Hyrimoz and an unbranded version of Humira, along with Biocon's near-copy drugs, will be preferred on CVS formularies.

Abbvie shares down as CVS moves to replace top selling arthritis drug with cheaper alternatives

CVS Caremark, the pharmaceutical subsidiary of CVS Health, announced Wednesday it will replace AbbVie's Humira from its list of covered drugs with cheaper alternatives for some customers—a move that's sure to take a chunk out of eye-popping Humira sales that have generated hundreds of billions for AbbVie.

CVS Partially Dropping Top-Selling Drug Humira In Favor Of Cheaper Biosimilars

CVS Health said on Wednesday it will remove AbbVie's blockbuster rheumatoid arthritis drug Humira from some of its lists of preferred drugs for reimbursement as of April 1, and will recommend biosimilar versions of the medicine instead.

CVS will remove AbbVie's Humira from some drug reimbursement lists in April

WOONSOCKET, R.I. , Jan. 3, 2024 /PRNewswire/ -- Today CVS Caremark®, a CVS Health® (NYSE: CVS) company, announced the continuation of its efforts to expand adoption of biosimilars.

CVS Caremark accelerates biosimilars adoption through formulary changes

CVS Health Corp (NYSE:CVS) has two things it didn't have during the past few years: a clear path to accelerating earnings growth; and appropriately reset expectations, according to Bank of America analysts.  In an update to clients, the analysts noted the healthcare company's earnings per share (EPS) targets of at least $8.50 in 2024 and 6% growth in 2025 are more than achievable.

CVS Health stock a top broker pick; faster earnings growth seen

In the closing of the recent trading day, CVS Health (CVS) stood at $78.62, denoting a +1.79% change from the preceding trading day.

CVS Health (CVS) Surpasses Market Returns: Some Facts Worth Knowing

Brookfield Renewable Partners

PayPal

Brookfield Renewable is poised for strong long-term growth as the demand for renewable energy increases. CVS Health is a bargain with an attractive dividend.

3 No-Brainer Stocks to Buy Right Now for Less than $100

Aflac

Broadstone Net Lease

Deere & Company

Kinder Morgan

Provident Financial Services

AT&T

Verizon

Growing your dividend income takes time and consistency.

Dividend Income Summary: Lanny's November 2023 Summary

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

Should You Invest in CVS Health (CVS) Based on Bullish Wall Street Views?

CVS Health's (CVS) restructuring plan poises it well, along with its strategic buyouts.

CVS Health (CVS) New Opportunities Drive Growth, Macro Woes Stay

WOONSOCKET, R.I. , Dec. 19, 2023 /PRNewswire/ -- CVS Health (NYSE: CVS) today announced that President and CEO Karen S.

CVS Health to present at the 42nd Annual J.P. Morgan Healthcare Conference

Devon Energy

OneMain Hld

TipRanks' analyst ranking service pinpoints Wall Street's best-performing stocks, including CVS Health and Devon Energy.

Top Wall Street analysts favor these 3 dividend stocks for the long haul

Archer-Daniels-Midland Company

Baker Hughes Co

Dow Inc

Energy Transfer LP Unit

Ford Motor Company

Kroger

MetLife

Pfizer

Philip Morris

Southern Company

Exxon Mobil

The Summer 2023 edition of Fortune Magazine revealed 500 biggest U.S. companies by revenue. Dogcatcher's quest to sniff out the best dividend buys focused on 68 industry leaders using YCharts 12/14/23 data. Those 68 industry leaders were segmented into 21 business sectors, ranging (alphabetically) from apparel to wholesalers. 3 of the 68 were private or foreign exchange listed firms not tracked by YCharts, leaving 65 listed. 58 dividend yielding stocks led those 68 industry leaders and ranged 0.17% to 9.08% in annual yield and ranged -15.07% to 36.4% in broker estimated one-year price target upsides by YCharts 12/14/23 reckoning.

4 Ideal December Dividend Fortune 500 Industry Leaders (Of 68)

Since its acquisition of health insurer Aetna in 2018, CVS has began to transform its business model from a brick-and-mortar pharmacy retailer to a fully integrated health care provider. Driven by a 2022 cutback in shareholder distributions and the announcement of two additional debt-funded acquisitions in primary care, shares have derated with growing investor concern on execution risk. Given strong performance in its insurance business and management having offered additional clarity on its mid-term strategy, I see favorable risk/reward skew with significant headroom for multiple rerating towards peers.

CVS Health: Risk/Reward Highly Skewed To The Upside

CVS's store receipts may stay long, but its prescription slips are about to get shorter.

Can CVS's Transparent Drug Pricing Cure An Industry Epidemic?

Alphabet

Spotify

Here are some of the major companies whose stocks moved on the week's news.

The Score: Spotify Technology, CVS Health, Alphabet and More Stocks That Defined the Week

CVS Health Corporation is a good fit for Warren Buffett's 10x Pretax Rule. Under this rule, paying 10x pretax earnings is already a good deal for a business even if it stagnates forever (as long as it does not shrink). CVS Health stock is for sale at 6.22x of its FWD pretax earnings.

News for CVS Health Stock (CVS)